The report studies highlight how AI-driven formulation design, process optimization, and real-time quality control are advancing pharmaceutical three-dimensional (3D) printing. Pharmaceutical companies, research institutions, and startups use machine learning (ML), predictive analytics, and generative AI to develop printable formulations, predict drug-release behavior, and optimize manufacturing parameters, reducing development time and experimental effort. These advances promote personalized medicine, on-demand drug production, and intelligent, automated manufacturing, demonstrating the growing scalability, efficacy, and clinical relevance of AI-integrated 3D printing across North America, Europe, and Asia-Pacific.
The report includes:
- Impact analysis of artificial intelligence (AI) on the global 3D-printed drugs market
- Case studies for successful integration of AI and machine learning in formulation design, dosage customization, print process optimization and quality control
- Highlights of AI adoption trends across major geographical regions, as well as disruptions caused by AI across key pharmaceuticals, drug delivery and additive manufacturing industry verticals
- AI’s role in personalized medicine, product development, manufacturing efficiency and regulatory compliance
- Review of AI impact on the various stages of the global 3D-printed drugs value chain and supply chain analysis
- Competitive landscape featuring key strategic initiatives, market spendings and an investment outlook
Table of Contents
Chapter 1 Key Use Cases for AI Adoption in the Global 3D Printing Drugs Market
Chapter 2 AI Adoption Trends
Chapter 3 AI Disruption Trends
Chapter 4 Market Spending and Investment Scenario
Chapter 5 Abbreviations
List of Tables
List of Figures
